Breast cancer is the most common malignancy in women accounting for between 20% and 32% of all cancers. It is estimated to cause 16% – 18% of all cancer deaths, representing the second cause of death, the first cause of death in women is lung cancer by 26%.
The highest incidence is observed in North America, while the lowest risk of breast cancer is found in Asia and Africa (Parkin et al, 2001). Lifetime risk for a woman to develop breast cancer is 1 in 7, with important consequences on the life of that person, her family and friends. Breast cancer is the second leading cause of cancer among US women, justifying almost 1 in 3 cancers diagnosed. Read more
Breast Cancer II
1. Ductal carcinoma in situ (DCIS) is 20-40% of all breast cancers and 5-10% of breast cancers in men. The risk of an invasive carcinoma is 25-50%. Most are ductal, ipsilateral appear in the same quadrant. 4 types have been described solid, cribriform, papillary and comedo. The incidence of positive axillary lymph nodes is 1-2%.
The recommended treatment is surgical treatment of axillary lymph node dissection conservative without associated with adjuvant radiotherapy. In patients with hormone receptor-positive recommended Tamoxifen 20mg / day for 5 years. Read further
III Breast Cancer
A. Adjuvant Hormone? Using immunohistochemistry RE / RP is usually considered positive when ≥ 10% of malignant cells are positive (weak or strong) either RE or for RP. Sometimes endocrine responses appear when weakly positive only 1-10% of tumor cells.
Tamoxifen only recommended in situations adjuvant hormonal therapy is tamoxifen 20 mg / day for 5 years. It is indicated in all patients with hormone receptor-positive or unknown, both for postmenopausal women how to premenopausal women. Not recommended in patients with ER and PR negative. We recommend using adjuvant endocrine therapy in patients with RH positive regardless of menopausal status, HER2 status / neu. Read more